Cantor Fitzgerald maintains AbbVie at Overweight, raises price target to $325 from $290
Cantor Fitzgerald kept its Overweight rating on AbbVie (ABBV) but increased its price target to $325 from $290, suggesting a 10.2% upside from the last close. Recent analyst targets for AbbVie range from $275 to $325.
How this was made
The 30-second read
Why it matters
The price target increase signals confidence in AbbVie's earnings outlook.
Market read
Analyst target raise may prompt short‑term buying pressure.
What to watch
Potential downside from upcoming earnings or pipeline risks.
Background
AbbVie is a large‑cap pharmaceutical company; analyst upgrades can move the stock.
Ticker impact
Cantor Fitzgerald raised its price target on AbbVie to $325 from $290, a 12.1% increase.
likely upward pressure as investors price in the higher target
The new target implies a 10% upside from the recent close, prompting buying interest.
Market effects
May lift sentiment in the pharmaceutical sector.
U.S. market focus on large‑cap pharma.
Limited to investors tracking U.S. health‑care stocks.
Counterpoint
Some investors may view the target raise as already priced in.
Key entities
- analystCantor Fitzgerald
Equity research firm that issued the upgraded target.
- companyAbbVie
U.S.-listed pharmaceutical company (ticker ABBV).
